PTSD


Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD

December 21st, 2021 - Ryan Allway

“Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder”   Vancouver, British Columbia–(Newsfile Corp. – December 21, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company“) is pleased to announce its patent-pending therapeutic regimen that has […]

Revitalist Executes on Vision to Become a Clinical Leader in Psychedelics

December 10th, 2021 - Ryan Allway

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) set out to build a nationwide network of psychedelic-assisted psychotherapy clinics in 2018. Since then, the company has grown its footprint to ten clinics across six states exceeding 60,650 sq. ft. of space and clinical capacity for more than 120 treatment rooms, with more […]

Cognetivity Neurosciences Partners with Ketamine One in Collaborative Clinical Study on Depression and PTSD

December 2nd, 2021 - Ryan Allway

Research study follows deployment of Cognetivity’s ICA in Ketamine One’s North American clinics and will open up novel, tailored use cases in burgeoning mental health market   VANCOUVER, BC, Dec. 2, 2021 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity“) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced that it is entering into a collaborative partnership […]

Ketamine Offers Promise to Veterans with PTSD

September 24th, 2021 - Ryan Allway

  Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the general population. PTSD manifests in many ways, ranging from depression to chronic fatigue. The FDA’s […]

MedXtractor Fills a Key Gap in Mental Health Treatments

June 30th, 2021 - Ryan Allway

  According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. MedXtractor Corp.’s (CSE: MXT) (OTC: […]

Microdosing: The Next Revolution in Psychedelics

April 22nd, 2021 - Ryan Allway

The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders. As states liberalize their psychedelics regulations, microdosing […]

Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference

April 15th, 2021 - Ryan Allway

NEW YORK, April 15, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities’ Neuroscience Conference, April 28-29, 2021.   Raj Mehra, Ph.D., Chairman and CEO, will present on Wednesday, April 28th at 11:00am ET. […]

Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.

April 6th, 2021 - Ryan Allway

NEW YORK, April 6, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the signing of an agreement between Seelos and AptarGroup, Inc. (NYSE: ATR) for the co-exclusive use and supply of Aptar Pharma’s Bidose (BDS) Liquid System device […]

Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer

April 6th, 2020 - Ryan Allway

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has […]

Psychedelics: Investing in the Perfect BrainStorm

April 6th, 2020 - Ryan Allway

Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space.  In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: […]

Cannabis Brands Want Their Own Store, CalEthos Deems it Essential

April 3rd, 2020 - Robin Lefferts

Cannabis Shelf Space Deemed Essential What is the ideal setting for a brand to showcase its wares to the retail consumer? It is certainly not a crowded store with hundreds of brands competing for limited shelf space and consumer attention. Every brand out there would much rather have its own store, featuring its own product […]

Psychedelics, the Next Frontier in Drug Research

March 1st, 2020 - Ryan Allway

A big factor in the recent rise of cannabis legalization is the emergence of legitimate scientific research into the potential health benefits of the plant’s active ingredients, called cannabinoids. Medicines are often derived from naturally occurring compounds, from aspirin to insulin to penicillin. A decent body of research is currently pointing to psilocybin, the psychedelic […]

Supreme Cannabis Announces Leadership Transition as Company Accelerates Transformation into Premium Cannabis CPG Company

January 6th, 2020 - Ryan Allway

Supreme Cannabis Board Director and former President of Starbucks Coffee Canada, Colin Moore, appointed Interim President and CEO. Navdeep Dhaliwal departs Company, effective immediately. Interim CEO to leverage successful track record to accelerate growth and transformation strategy, while improving speed to market and rightsizing operating and capital spends. Search for new CEO to begin immediately. […]

The Two Areas Where Large-Scale Cannabis Farming is Legal in California

December 3rd, 2019 - Ash Stringer

Famously known for its vineyards, the rolling hills of Santa Barbara, California and, 200 miles to the north, the Salinas Valley, once the rose capital of the world, have transformed into new commerce hubs: cannabis. As the only areas of California currently allowing large-scale cannabis cultivation, companies looking to get an upper hand on market […]

Supreme’s 7ACRES Continues to Impress

November 14th, 2019 - Ash Stringer

2018 was a stellar year for cannabis advocates as the green rush of marijuana legalization swept the globe, including California, the world’s fifth biggest economy, legalizing recreational marijuana and Canada becoming the first G20 nation to do so; however, 2019 may go down – surprisingly – as the year of a cannabis shake-out. Despite retreating […]

Snoop Dogg “Down With” Israeli Cannabis Company, Highlights Investment in the Country

October 30th, 2019 - Ash Stringer

Vocal cannabis activist Snoop Dogg has signed on as a brand ambassador for Israeli start-up Seedo (OTC: SEDO), the maker of a refrigerator-type of a machine for auto-growing plants, including cannabis. The indelible award-winning rapper says he’s “all the way down with” the Seedo Homelab and the utility it brings to allow people to grow […]

New Report: Women Prefer Cannabis Strains High in CBD

October 30th, 2019 - Ryan Allway

RYAH Finds Top Priority is Treating Mental Health, Over 28,000 Women Surveyed New York, NY, October 30, 2019 – RYAH Medtech, Inc. (“RYAH” or the “Company”), a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry, has released a data analytics report on women and their medical […]

Isracann Biosciences Launches Phase One Facility Development Program in Israel

October 28th, 2019 - Ryan Allway

Company aims to develop top regional cannabis brands for entry into EU marketplace VANCOUVER, British Columbia, Oct. 28, 2019 (GLOBE NEWSWIRE) — Isracann Biosciences Inc.  (CSE: IPOT) formerly Atlas Blockchain Group Inc. (CSE: AKE) (XFRA: A2PT0E) (OTC: ATLED) (the “Company”) is pleased to provide an operative overview and update regarding facility development activities in Israel. Concurrent to […]

Benzinga Cannabis Capital Conference Connecting Cannabis Investors & Executives in Chicago

October 21st, 2019 - Ryan Allway

The Benzinga Cannabis Capital Conference will take place at Chicago’s Palmer House on October 22 and 23, 2019. Cannabis investors will have a chance to come face-to-face with cannabis companies to hear about their advancements in the rapidly growing industry, while cannabis executives will have an opportunity to grow their business and attract investors with […]

DNA Genetics Names Rakaa Taylor as Director of Marketing

October 15th, 2019 - Ryan Allway

Leading Global Cannabis Brand Selects Seasoned Marketing Manager, Brand Specialist, Creative Director and Hip Hop Veteran to Head Marketing Operations LOS ANGELES, Oct. 01, 2019 (GLOBE NEWSWIRE) — OG DNA Genetics (“DNA”, “DNA Genetics”, or the “Company”), a globally recognized leading cannabis brand, announced today that Rakaa Taylor will be joining the executive team as […]

A Leader In Washington, GreenStar Eyes Expansion

September 10th, 2019 - Ash Stringer

Washington State has long been a pioneer in the cannabis industry. Medical marijuana has been legal since 1998 and the state was the first in the U.S. to approve recreational marijuana, doing so on December 6, 2012. The market continues to grow, including retail sales reaching $972 million in 2018 from $851 million in 2017. […]

A Look Under the Rug at the Savvy Penetration of Europe’s Cannabis Market by Supreme Heights

September 6th, 2019 - Ryan Allway

As the nascent European legal cannabis market emerges, Canadian companies that have cut their teeth in their home markets are taking that experience overseas to capitalize on a much larger market opportunity. The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) is a model of how to build a successful cannabis portfolio at a blistering […]

DNA Genetics’ Charles Phillips Talks Cannabis Branding with CFN Media

August 5th, 2019 - Ash Stringer

As the cannabis market moves from the back alley to the boardroom, we are gaining an increasing appreciation for the role genetics play in developing distinct varieties with unique medical and commercial application. As the cannabis market matures, the significance of genetic selection is quickly becoming a focus of the discussion. Cannabis has been loosely […]

Supreme Cannabis: At the Epicenter of Premium Products

July 22nd, 2019 - Ash Stringer

The old Aesop axiom advises to be vigilant, for you can be known by the company that you keep. If that’s the case, then Supreme Cannabis (TSX:FIRE) (OTCQX:SPRWF) must feel pretty good, as it has surrounded itself with household names in the burgeoning cannabis industry, albeit in-house, through partnerships or association. In-House Supreme is not […]

FSD Pharma Brings in World-Renowned Experts to Build Bioscience Division

June 4th, 2019 - Ryan Allway

The cannabis industry is quickly maturing from home grows and bongs to industrial-scale cultivation and innovative new product formats. At the core of this transformation, science is helping transform medical cannabis into cutting-edge pharmaceuticals and recreational cannabis into compelling alternatives to tobacco and alcohol. Companies that recognize the role of science are best positioned to […]

Grown Rogue Talks Growth Strategy in Exclusive Interview

May 13th, 2019 - Ryan Allway

Multi-state operators, or MSOs, have become increasingly common across the United States given their economies of scale. With the industry’s relatively easy access to capital, many of these MSOs have bought up assets at all costs to rapidly build a footprint. Investors may want to avoid some of these companies and seek out those that […]

FSD Pharma Doubles Down on Endocannabinoid-based Pain Management

May 1st, 2019 - Ryan Allway

Chronic pain is a widespread condition affecting about one-third of the American population and billions of other people around the world. Despite their widely known dangers, opioids quickly became one of the most prescribed and profitable classes of drugs in the world. The ensuing opioid crisis has made overdoses a leading cause of non-disease deaths […]

Halo Expands Branded Products & Launches Hemp CBD Products

April 24th, 2019 - Ryan Allway

The cannabis industry is projected to reach $146.4 billion by 2025, according to Grand View Research, driven by the legalization of recreational cannabis across a growing number of states and countries. While there are many different opportunities in the space, there are only a handful of companies that have proven their ability to generate significant […]

Pascal Biosciences Commences Cannabinoid Testing of Human Volunteers and Patients

January 24th, 2019 - Ryan Allway

VANCOUVER, British Columbia, and SEATTLE, Jan. 24, 2019 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the testing of cannabinoids in human subjects for its immune stimulatory program in cancer. Furthermore, the Company has filed an international patent application to protect this work for […]

CFN Media’s Exclusive Executive Interview With Grown Rogue on Michigan Expansion

January 23rd, 2019 - Ryan Allway

The cannabis industry is projected to generate upwards of $80 billion in revenue by 2022, according to Marijuana Business Daily, driven by the legalization of medical and recreational cannabis across a growing number of states. Investors may want to keep an eye on companies that capture market share early on in a state’s legalization efforts, […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading